 CRANBURY, N.J., Sept. 27, 2021 PRNewswire -- Palatin Technologies, Inc. NYSE American: PTN, a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced the presentation of the protective effects of melanocortin 1 receptor agonists PL8331 and PL9654 in mouse models of retinopathy, at the 2021 Annual Meeting of the American Society of Retina Specialists ASRS, being held virtually October 8-12, 2021. 